Clinical Trial Update: Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer [Phase 2]

View source ↗

Summary

Phase II trial of pazopanib in combination with weekly paclitaxel in refractory urothelial cancer has completed, with results posted on 2017-06-09.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Urothelial Carcinoma of the Bladder

Drugs mentioned

• Paclitaxel (Taxol) (paclitaxel)
• Pazopanib (Votrient) (Pazopanib)

Snippet

Sponsor: Sandy Srinivas | Conditions: Bladder Cancer, Bladder (Urothelial, Transitional Cell) Cancer | Phase 2 | Status: COMPLETED | Results posted: 2017-06-09